Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

As a result, 2025 could be a bumper year for the biopharma and clinical trial industries. Data capture will surge in popularity In an era when AI-driven data tools reign supreme, clinical trials ...

Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. The strategic options being ...

Tinnitus affects up to 43% of people depending on definitions and populations studied. This phantom perception of sound can ...

India's new drug approval process waiver raises concerns about patient safety, research, and healthcare implications, experts ...

Men are underrepresented in health research, particularly lifestyle change trials. This study explores why, revealing ...

The myTomorrows search function now includes the ISRCTN while its platform has added AI eligibility checking for clinical ...

China: A new randomized clinical trial has demonstrated that QX004N, a humanized anti-IL-23 monoclonal antibody, offers ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...

The Eclipse Trial is researching an investigational vaccine to protect against Epstein-Barr virus (EBV) and infectious ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.